AU2013237275B2 - Process for determining the susceptibility to nosocomial infections - Google Patents

Process for determining the susceptibility to nosocomial infections Download PDF

Info

Publication number
AU2013237275B2
AU2013237275B2 AU2013237275A AU2013237275A AU2013237275B2 AU 2013237275 B2 AU2013237275 B2 AU 2013237275B2 AU 2013237275 A AU2013237275 A AU 2013237275A AU 2013237275 A AU2013237275 A AU 2013237275A AU 2013237275 B2 AU2013237275 B2 AU 2013237275B2
Authority
AU
Australia
Prior art keywords
scd127
patient
sample
expression
septic shock
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013237275A
Other languages
English (en)
Other versions
AU2013237275A1 (en
Inventor
Alain Lepape
Guillaume Monneret
Fabienne VENET
Astrid VILLARS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomerieux SA
Hospices Civils de Lyon
Original Assignee
Biomerieux SA
Hospices Civils de Lyon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomerieux SA, Hospices Civils de Lyon filed Critical Biomerieux SA
Publication of AU2013237275A1 publication Critical patent/AU2013237275A1/en
Application granted granted Critical
Publication of AU2013237275B2 publication Critical patent/AU2013237275B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29B—PREPARATION OR PRETREATMENT OF THE MATERIAL TO BE SHAPED; MAKING GRANULES OR PREFORMS; RECOVERY OF PLASTICS OR OTHER CONSTITUENTS OF WASTE MATERIAL CONTAINING PLASTICS
    • B29B15/00—Pretreatment of the material to be shaped, not covered by groups B29B7/00 - B29B13/00
    • B29B15/08—Pretreatment of the material to be shaped, not covered by groups B29B7/00 - B29B13/00 of reinforcements or fillers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C35/00—Heating, cooling or curing, e.g. crosslinking or vulcanising; Apparatus therefor
    • B29C35/02—Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould
    • B29C35/0266—Local curing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C70/00—Shaping composites, i.e. plastics material comprising reinforcements, fillers or preformed parts, e.g. inserts
    • B29C70/04—Shaping composites, i.e. plastics material comprising reinforcements, fillers or preformed parts, e.g. inserts comprising reinforcements only, e.g. self-reinforcing plastics
    • B29C70/06—Fibrous reinforcements only
    • B29C70/10—Fibrous reinforcements only characterised by the structure of fibrous reinforcements, e.g. hollow fibres
    • B29C70/16—Fibrous reinforcements only characterised by the structure of fibrous reinforcements, e.g. hollow fibres using fibres of substantial or continuous length
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C70/00—Shaping composites, i.e. plastics material comprising reinforcements, fillers or preformed parts, e.g. inserts
    • B29C70/04—Shaping composites, i.e. plastics material comprising reinforcements, fillers or preformed parts, e.g. inserts comprising reinforcements only, e.g. self-reinforcing plastics
    • B29C70/28—Shaping operations therefor
    • B29C70/30—Shaping by lay-up, i.e. applying fibres, tape or broadsheet on a mould, former or core; Shaping by spray-up, i.e. spraying of fibres on a mould, former or core
    • B29C70/38—Automated lay-up, e.g. using robots, laying filaments according to predetermined patterns
    • B29C70/382—Automated fiber placement [AFP]
    • B29C70/384—Fiber placement heads, e.g. component parts, details or accessories
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C35/00—Heating, cooling or curing, e.g. crosslinking or vulcanising; Apparatus therefor
    • B29C35/02—Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould
    • B29C2035/0211—Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould resistance heating
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C53/00—Shaping by bending, folding, twisting, straightening or flattening; Apparatus therefor
    • B29C53/56—Winding and joining, e.g. winding spirally
    • B29C53/58—Winding and joining, e.g. winding spirally helically
    • B29C53/581—Winding and joining, e.g. winding spirally helically using sheets or strips consisting principally of plastics material
    • B29C53/582—Winding and joining, e.g. winding spirally helically using sheets or strips consisting principally of plastics material comprising reinforcements, e.g. wires, threads
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2101/00—Use of unspecified macromolecular compounds as moulding material
    • B29K2101/10—Thermosetting resins
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
    • B29K2105/24—Condition, form or state of moulded material or of the material to be shaped crosslinked or vulcanised
    • B29K2105/243—Partially cured
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Mechanical Engineering (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Composite Materials (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Robotics (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Thermal Sciences (AREA)
  • Textile Engineering (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Surgery (AREA)
  • Medical Informatics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Materials Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
AU2013237275A 2012-03-23 2013-03-22 Process for determining the susceptibility to nosocomial infections Ceased AU2013237275B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1252641 2012-03-23
FR1252641A FR2988479B1 (fr) 2012-03-23 2012-03-23 Procede de determination de la susceptibilite aux infections nosocomiales
PCT/FR2013/050624 WO2013140103A1 (fr) 2012-03-23 2013-03-22 Procédé de détermination de la susceptibilité aux infections nosocomiales

Publications (2)

Publication Number Publication Date
AU2013237275A1 AU2013237275A1 (en) 2014-10-02
AU2013237275B2 true AU2013237275B2 (en) 2018-07-05

Family

ID=48237069

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013237275A Ceased AU2013237275B2 (en) 2012-03-23 2013-03-22 Process for determining the susceptibility to nosocomial infections

Country Status (9)

Country Link
US (2) US9823239B2 (cg-RX-API-DMAC7.html)
EP (1) EP2828657B9 (cg-RX-API-DMAC7.html)
JP (2) JP6162788B2 (cg-RX-API-DMAC7.html)
CN (1) CN104246499B (cg-RX-API-DMAC7.html)
AU (1) AU2013237275B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014023387B1 (cg-RX-API-DMAC7.html)
ES (1) ES2573807T3 (cg-RX-API-DMAC7.html)
FR (1) FR2988479B1 (cg-RX-API-DMAC7.html)
WO (1) WO2013140103A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2988479B1 (fr) * 2012-03-23 2014-12-19 Hospices Civils Lyon Procede de determination de la susceptibilite aux infections nosocomiales
FR3010792B1 (fr) * 2013-09-18 2017-03-17 Biomerieux Sa Procede d'evaluation du risque de mortalite chez les patients qui presentent une reponse inflammatoire systemique (sirs) ou des syndromes septiques
FR3044325B1 (fr) 2015-12-01 2019-05-03 Biomerieux Procede d'evaluation du risque de complications chez les patients qui presentent un syndrome de reponse inflammatoire systemique (sirs)
CN108922620A (zh) * 2018-06-20 2018-11-30 南华大学 一种手术切口感染风险评估系统
FR3112209A1 (fr) * 2020-07-06 2022-01-07 bioMérieux Procédé pour déterminer le risque de complication chez un patient
FR3112207A1 (fr) * 2020-07-06 2022-01-07 bioMérieux Procédé pour déterminer le risque de survenue d’une infection associée aux soins chez un patient
FR3112208A1 (fr) * 2020-07-06 2022-01-07 bioMérieux Procédé pour déterminer le risque de survenue d’une infection associée aux soins chez un patient
FR3112211A1 (fr) * 2020-07-06 2022-01-07 bioMérieux Procédé pour déterminer le risque de survenue d’une infection associée aux soins chez un patient

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2941240A1 (fr) * 2009-01-19 2010-07-23 Biomerieux Sa Procede pour determiner la sensibilite d'un patient a contracter une infection nosocomiale.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444879A (en) * 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
FI915911A7 (fi) * 1989-06-15 1991-12-16 Immunex Corp Interleukiini-7-reseptoreja
JP2007522118A (ja) * 2004-01-30 2007-08-09 ペプリン バイオリピッズ ピーティーワイ エルティーディー 治療用分子および担体分子
ZA200701662B (en) * 2004-07-27 2009-06-24 Medmined Inc Method for measuring the incidence of hospital acquirede infections
US20100035240A1 (en) * 2004-08-10 2010-02-11 Cardiff Biologicals Limited Methods and kit for the prognosis of breast cancer
DE102008000715B9 (de) * 2008-03-17 2013-01-17 Sirs-Lab Gmbh Verfahren zur in vitro Erfasssung und Unterscheidung von pathophysiologischen Zuständen
TW201018482A (en) * 2008-08-08 2010-05-16 Glaxo Wellcome Mfg Pte Ltd Novel treatment
WO2010041232A2 (en) * 2008-10-09 2010-04-15 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin A method of estimating sepsis risk in an individual with infection
EP2379752B1 (fr) * 2009-01-19 2015-09-30 Biomérieux S.A. Procedes pour determiner la susceptibilite a contracter une infection nosocomiale chez un patient et pour etablir un pronostic d'evolution d'un syndrome septique
FR2988479B1 (fr) * 2012-03-23 2014-12-19 Hospices Civils Lyon Procede de determination de la susceptibilite aux infections nosocomiales
WO2014106604A1 (en) * 2013-01-03 2014-07-10 Unilever Plc Hair care composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2941240A1 (fr) * 2009-01-19 2010-07-23 Biomerieux Sa Procede pour determiner la sensibilite d'un patient a contracter une infection nosocomiale.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CAROLINE LANDELLE ET AL, INTENSIVE CARE MEDICINE, SPRINGER, BERLIN, DE, (2010-07-23), vol. 36, no. 11, ISSN 1432-1238, pages 1859 - 1866 *

Also Published As

Publication number Publication date
CN104246499B (zh) 2017-05-10
JP2017198692A (ja) 2017-11-02
EP2828657B9 (fr) 2016-08-24
JP2015513097A (ja) 2015-04-30
US10725029B2 (en) 2020-07-28
BR112014023387B1 (pt) 2022-05-17
US9823239B2 (en) 2017-11-21
US20150064728A1 (en) 2015-03-05
WO2013140103A1 (fr) 2013-09-26
EP2828657B1 (fr) 2016-03-16
JP6458087B2 (ja) 2019-01-23
US20180111342A1 (en) 2018-04-26
CN104246499A (zh) 2014-12-24
FR2988479B1 (fr) 2014-12-19
AU2013237275A1 (en) 2014-10-02
BR112014023387A2 (cg-RX-API-DMAC7.html) 2017-06-20
JP6162788B2 (ja) 2017-07-12
FR2988479A1 (fr) 2013-09-27
ES2573807T3 (es) 2016-06-10
EP2828657A1 (fr) 2015-01-28

Similar Documents

Publication Publication Date Title
US10725029B2 (en) Kit for in vitro or ex vivo measurement of SCD127 expression in a biological sample
Perriard et al. Interleukin-22 is increased in multiple sclerosis patients and targets astrocytes
CN102203619B (zh) 慢性肾病中的预测方法
Liang et al. Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73
Rose et al. Identification and biochemical characterization of human plasma soluble IL-7R: lower concentrations in HIV-1-infected patients
Osterburg et al. NK cell activating receptor ligand expression in lymphangioleiomyomatosis is associated with lung function decline
Tinholt et al. Syndecan-3 and TFPI colocalize on the surface of endothelial-, smooth muscle-, and cancer cells
WO2018224506A2 (en) Auto immune diagnosis using t cell populations
Lima et al. Low thymic output in the 22q11. 2 deletion syndrome measured by CCR9+ CD45RA+ T cell counts and T cell receptor rearrangement excision circles
US20200256876A1 (en) KIT FOR IN VITRO OR EX VIVO MEASUREMENT OF THE EXPRESSION OF sCD127 IN A BIOLOGICAL SAMPLE
Subhi‐Issa et al. Myeloid‐derived suppressor cells as a potential biomarker for recurrent pregnancy loss and recurrent implantation failure: increased levels of Mdscs in recurrent reproductive failure
Bunting et al. CCR6 supports migration and differentiation of a subset of DN1 early thymocyte progenitors but is not required for thymic nTreg development
Bahabayi et al. Reduced TRIM expression correlates with anomalous CD4 T cell activation in systemic lupus Erythematosus and its clinical diagnostic potential
US20230168243A1 (en) Methods for diagnosing immediate hypersensitivy reaction
Matsunaga et al. Long-term follow-up of production of IgM and IgG antibodies against SARS-CoV-2 among patients with COVID-19
Maulicino Investigating the Role of Immune Response Markers in Predicting Severity and Prognosis in COVID-19 Patients: A Retrospective Study from the ASL1 Emergency Department
Du et al. Simultaneous detection of serum immunoglobulin G antibodies to Cryptosporidium parvum by multiplex microbead immunoassay using 3 recognized specific recombinant C. parvum antigens
WO2022258252A1 (en) Biomarker for monitoring coronavirus disease 2019
Bienzle et al. American Society for Veterinary Clinical Pathology (ASVCP) 46th Annual Meeting
WO2010099568A1 (en) Biomarkers for chronic fatigue syndrome

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired